profit from every $100 of sales.
$0$100
Atara Biotherapeutics
$7.70-2.90% today
-42.5% in 1 year
1-year low $4.181-year high $18.09
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay $2.40 for every $1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Atara Biotherapeutics sold, what it kept, and what it did with the cash.
Sales went from $63.6 million in 2022 to $121 million in 2025, with $32.7 million of profit last year.
SalesProfit
Atara Biotherapeutics vs. similar companies
Atara Biotherapeutics grows the fastest of these 5 and is the cheapest for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Atara Biotherapeutics | 2.4× · Cheap | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Atara Biotherapeutics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 64 | 9 | 129 | 121 | |
| 64 | -0 | 108 | 100 | |
| -281 | -276 | -83 | 36 | |
| -222 | -266 | -76 | 39 | |
| -228 | -276 | -85 | 33 | |
| -56.00 | -65.19 | -11.41 | 2.57 | |
| 100.0% | -3.7% | 83.7% | 82.4% | |
| -441.2% | -3,219.5% | -64.7% | 29.7% | |
| -359.1% | -3,220.9% | -66.2% | 27.1% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 376 | 166 | 109 | 20 |
| Cash | 93 | 26 | 25 | 8 |
| Total debt | 72 | 58 | 44 | 10 |
| Total liabilities | 250 | 265 | 206 | 59 |
| 127 | -99 | -97 | -39 | |
| 4 | 4 | 7 | 13 | |
| -90.8% | – | – | – | |
| -180.3% | 278.3% | 87.8% | -84.9% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -270 | -193 | -69 | -51 | |
| 4 | 1 | 0 | – | |
| -275 | -194 | -69 | -51 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 54 | 45 | 27 | 10 |
Valuation
- 2.4×
- –
- –
- -2.7×
- 0.6×
- –
- 2.1×
- -64.9%
- 41.7%
- 0.0%
Profitability
- 82.4%
- 29.7%
- 27.1%
- 30.9%
- 222.7%
- 166.1%
- -79.1%
- 161.5%
- 675.0%
- 31.4%
Growth
- +23.9%
- –
- +26.1%
- –
- +35.3%
Financial health
- 1.2×
- -1.37
- 260.9%
- 9.5×
- 0.82
- 0.82
- 5.97
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 10%of 872
Top 1%of 563
Top 24%of 868
Bottom 1%of 986
What analysts expect
- Average price target
- $15.50
- Range
- $6.00 – $25.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 12, 2026 | -0.29 | -0.33 | +12.0% |
| Mar 16, 2026 | -0.25 | -0.09 | −177.8% |
| Nov 12, 2025 | -0.32 | -0.83 | +61.4% |
| Aug 11, 2025 | 0.19 | -0.32 | +159.4% |
| May 15, 2025 | 3.50 | -3.07 | +214.0% |
| Mar 7, 2025 | -1.19 | -3.82 | +68.8% |
| Nov 12, 2024 | -2.93 | -3.77 | +22.3% |
| Aug 12, 2024 | -3.10 | -1.25 | −148.0% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
7/7Passes 7 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
70Pass
Benjamin Graham
63Pass
Philip Fisher
82Pass
Peter Lynch
100Pass
Joel Greenblatt
100Pass
Charlie Munger
69Pass
Terry Smith
67Pass
Questions about Atara Biotherapeutics
Is Atara Biotherapeutics a good stock to buy?
A strong, very profitable business, and the price looks low. 7 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Atara Biotherapeutics AI analysis
What does Atara Biotherapeutics do?
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is in Biotechnology.
Does Atara Biotherapeutics pay a dividend?
No. Atara Biotherapeutics does not pay a dividend at the moment.
Is Atara Biotherapeutics stock halal?
Yes. Atara Biotherapeutics passes our halal screen: its business is permitted and its debt is 13% of its market value, under the 30% limit. How we check
How has Atara Biotherapeutics stock done over the past year?
Down 42.5% over the past twelve months, to $7.70. It traded between $4.18 and $18.09 and is 57.4% below its high.
Who are Atara Biotherapeutics's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Atara Biotherapeutics's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.